Concepedia

S. Thongprasert

ST

Statistics

Publications

4

Citations

726

H-Index

4

Active since

1984

Affiliations

New Cross Hospital(Current)

S. Thongprasert is an author at New Cross Hospital specializing in oncology, chemotherapy, and lung cancer.

Publications per year

1984–2009

4

Publications

4

Systemic candidiasis in cancer patients.

Andrew W. Maksymiuk, S. Thongprasert, Roy L. Hopfer et al. · PubMed · 1984 · 272 citations

, , +14

A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1<sup>st</sup> line or 2<sup>nd</sup> line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · Journal of Clinical Oncology · 2004 · 263 citations

, , +9

Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)

M. Fukuoka, Yi‐Cheng Wu, S. Thongprasert et al. · Journal of Clinical Oncology · 2009 · 119 citations

, , +13

Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)

Ronald B. Natale, S. Thongprasert, F. Anthony Greco et al. · Journal of Clinical Oncology · 2009 · 72 citations

, , +14

1–4 of 4